{"title":"罕见癌症,继续前进的议程-编辑的特别前言","authors":"D. O’Connor","doi":"10.1080/21678707.2020.1821529","DOIUrl":null,"url":null,"abstract":"Rare cancers affect one in five new patients with cancer and this second special edition highlights some of the continued activity in the field (first special edition[1]). Of note since the first s...","PeriodicalId":12118,"journal":{"name":"Expert Opinion on Orphan Drugs","volume":"8 1","pages":"309 - 310"},"PeriodicalIF":0.8000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21678707.2020.1821529","citationCount":"0","resultStr":"{\"title\":\"Rare cancers, the continued agenda for progress – editor’s special foreword\",\"authors\":\"D. O’Connor\",\"doi\":\"10.1080/21678707.2020.1821529\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rare cancers affect one in five new patients with cancer and this second special edition highlights some of the continued activity in the field (first special edition[1]). Of note since the first s...\",\"PeriodicalId\":12118,\"journal\":{\"name\":\"Expert Opinion on Orphan Drugs\",\"volume\":\"8 1\",\"pages\":\"309 - 310\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2020-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21678707.2020.1821529\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Orphan Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21678707.2020.1821529\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Orphan Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678707.2020.1821529","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Rare cancers, the continued agenda for progress – editor’s special foreword
Rare cancers affect one in five new patients with cancer and this second special edition highlights some of the continued activity in the field (first special edition[1]). Of note since the first s...